ImmuCell Corporation (ICCC)

Several events have impacted ImmuCell Corp.'s stock price in the past six months, including an FDA Incomplete Letter for Re-Tain in December 2025, which led to a strategic focus on First Defense. Preliminary sales results for Q4 2025 showed a slight decline in total sales but an increase in domestic sales. The company released its third-quarter 2025 earnings, reporting a US$0.015 loss per share, an improvement from a US$0.086 loss in Q3 2024. Market capitalization has fluctuated, with a significant increase in June 2025 and a decrease in December 2025. Investor sentiment improved in December 2025 but deteriorated in November 2025.

Demand for ImmuCell Corp.'s products, particularly the First Defense product line, exhibits seasonality, with higher sales typically observed during the first quarter due to the beef calving season. Extreme weather conditions can also influence demand. The company has faced challenges in meeting customer demand due to production capacity constraints and past contamination events.

ImmuCell Corporation is an animal health company focused on developing, manufacturing, and marketing products to enhance the health and productivity of dairy and beef cattle, operating within the Healthcare sector, specifically in the Biotechnology industry, with a primary focus on Scours and Mastitis. Its major products include the First Defense product line, an orally delivered preventive product for calves targeting scours, Re-Tain, a novel purified Nisin product for dairy cows developed as an intramammary treatment for subclinical mastitis, and the California Mastitis Test, a quick on-farm diagnostic tool used to detect somatic cell counts in milk and identify mastitic udder quarters.

ImmuCell Corporation develops, manufactures, and sells its products in the United States and internationally and is actively pursuing regulatory approvals for its First Defense product line in selected international territories. While international sales saw a decline in Q4 2025, largely due to order timing, domestic sales increased.

ImmuCell's brand reputation has been influenced by its leadership position in the U.S. market for scour-prevention, with its First Defense product line ranking #1. However, the company has acknowledged brand damage from supply shortages and the recent FDA Incomplete Letter for Re-Tain could negatively impact its reputation.

As of September 30, 2025, the ownership of ImmuCell Corp. is distributed as follows: 48.32% is held by public and other entities, 28.06% by individuals/insiders, 18.06% by institutions, and 5.55% by hedge fund managers. P. F. Te Boekhorst, CEO, directly owns 0.11% of the company's shares.